Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic’s production ...

Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat ...

Produced using Dyadic’s proprietary high-yield fungal microbial expression platforms and Fermbox Bio’s scale-up and biomanufacturing capabilities, Recombinant DNase I (RNase-free) is currently ...

Our animal-origin free recombinant proteins and enzymes portfolio, developed with Dyadic, augments Fermbox’s strategy of developing products that balance commercial scale with strong margin potential.

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases ...

In addition to OEM distribution, the collaboration provides flexibility for potential future expansion, which could include Dyadic supplying market-ready products for distribution or licensing ...

Kismai is a savant when it comes to getting clothes clean.

For most children with complicated pneumonia, a less aggressive treatment approach is favored for those with small or ...

Dyadic Applied BioSolutions (NASDAQ: DYAI) shares advanced Monday. The Jupiter, Fla.-based company, a global biotechnology concern producing precision-engineered, animal-free proteins and enzymes for ...

Company to host conference call and webcast today at 8:00 a.m. EDT The European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio® ...

Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company producing precision-engineered ...